God morgen <3
https://newsweb.oslobors.no/message/504447
Targovax releases update for mesothelioma trial combining ONCOS-102 and chemotherapy
· Progression free survival at the 9-month follow-up is tracking in line with
previously published data
· Immune activation is further validated in the ONCOS-102 treated group
· First line mesothelioma remains the focus for next phase of development
Oslo, Norway, 4 May 2020 - Targovax ASA (OSE: TRVX), a clinical stage immuno
-oncology company developing oncolytic viruses to target hard-to-treat solid
tumors, today releases an update from the randomized phase I/II trial of ONCOS
-102 in combination with standard of care chemotherapy in malignant pleural
mesothelioma.
The trial is an open label, randomized, exploratory phase I/II trial adding
ONCOS-102 to standard of care (SoC) chemotherapy (pemetrexed/cisplatin) in first
and second (and later) line mesothelioma to assess safety, immune activation and
clinical efficacy. In total, 31 patients have been enrolled with 20 patients in
the experimental group receiving the ONCOS-102 and SoC, and 11 patients in a
control group receiving SoC only. The first set of data was reported in January
2020, see link to press release here (https://www.targovax.com/en/targovax
-announces-encouraging-data-in-mesothelioma-study-combining-oncos-102-and
-standard-of-care-chemotherapy/).
All patients have now completed the 9-month follow-up. The median Progression
Free Survival (mPFS) remains in line with previously published data and compares
favorably with historical control. The first line patients continue to perform
well, and will be the population prioritized for future development. The updated
PFS data are being complemented by biomarker analyses and early data demonstrate
enhanced immune activation and modulation of tumor microenvironment in ONCOS-102
-treated patients compared to the control group. 12-months clinical data as well
as more extensive immune activation and biomarker data will be released in the
middle of 2020.
Dr. Magnus Jäderberg, Chief Medical Officer of Targovax, said: “We are very
pleased to see the encouraging early PFS figures holding up in the 9-month
analysis. The data look particularly promising for first line patients, and the
preparations for a subsequent checkpoint inhibitor combination trial in this
population with a big pharma collaboration partner are progressing according to
plan”.
